Chronic Kidney Disease

ESC 2021: Finerenone Now Shows Promise in Less Severe Diabetic Kidney Disease
August 30, 2021

Finerenone, in patients with mild-to-moderate renal disease and T2D, reduced CV event risk by 13% and risk for a composite renal event by 23%, study authors reported at ESC 2021.

European Society of Cardiology Congress 2021: Primary Care Preview
August 26, 2021

The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.

Finerenone Approved as First-in-Class Treatment for Chronic Kidney Disease Associated with Type 2 Diabetes
July 12, 2021

The first nonsteroidal mineralocorticoid receptor antagonist to be approved for adults with T2D-associated CKD fills a significant treatment void for millions of patients.